Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture
Bioprocess and Biosystems Engineering · 2026-08 · 49 (8) · 2033-2043
DOI: 10.1007/s00449-026-03358-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioprocess and Biosystems Engineering, online erschienen am 27.05.2026. Verfasst von Elcin Cagatay und 3 weiteren Autor:innen. Beteiligte Einrichtung: Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Batch Cell Culture Techniques. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dokuz Eylül University.
Abstract (Originalsprache)
The development of biosimilar monoclonal antibodies requires strict control of critical quality attributes and a detailed understanding of cell culture performance. This study describes the development and preliminary physicochemical characterization of a candidate biosimilar monoclonal antibody targeting VEGFR-2 produced in CHO cells. Seventy-five clones generated through gene transfection were screened based on productivity and cell viability. Culture parameters including pH, glucose concentration, cell growth, and cell specific productivity (Qp) were monitored to evaluate their influence on production performance. Eight high producing clones were selected for shake-flask scale fed-batch production. The lead clone achieved a final titer of 2.79 g/L. The biosimilar candidates were characterized using intact mass spectrometry, size exclusion chromatography, cation exchange chromatography, hydrophobic interaction chromatography, glycan analysis, and peptide mapping. Binding affinities were evaluated using SPR, demonstrating comparable interaction with VEGFR-2. The analytical results demonstrated structural similarity to the reference product with no critical differences in purity, charge variants, glycosylation patterns, or binding affinity. These findings demonstrate the importance of systematic clone screening and upstream process monitoring for achieving consistent product quality in biosimilar antibody production and provide practical insights for mammalian cell-based bioprocess development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey.
- Izmir Biomedicine and Genome Center, Izmir, Turkey.
- OzBio LLC, Dedham, MA, USA.
- Izmir International Biomedicine and Genome Institute, Dokuz Eylul University, Izmir, Turkey. hulya.kayali@deu.edu.tr.
- Izmir Biomedicine and Genome Center, Izmir, Turkey. hulya.kayali@deu.edu.tr.
- Department of Chemistry, Faculty of Science, Dokuz Eylul University, Izmir, Turkey. hulya.kayali@deu.edu.tr.
Förderung
- Dokuz Eylül University
Zitieren
APA
Cagatay, E., Gungor, Y., Ozturk, S. S., & Kayali, H. A. (2026). Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture. Bioprocess and Biosystems Engineering, 49(8), 2033-2043. https://doi.org/10.1007/s00449-026-03358-y
Vancouver
Cagatay E, Gungor Y, Ozturk SS, Kayali HA. Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture. Bioprocess and Biosystems Engineering. 2026;49(8):2033-2043. doi:10.1007/s00449-026-03358-y
BibTeX
@article{Cagatay2026,
author = {Cagatay, Elcin and Gungor, Yonca and Ozturk, Sadettin S and Kayali, Hulya Ayar},
title = {Development and preliminary physicochemical characterization of a Ramucirumab biosimilar candidate in CHO cells using shake-flask fed-batch culture},
journal = {Bioprocess and Biosystems Engineering},
year = {2026},
volume = {49},
number = {8},
pages = {2033--2043},
doi = {10.1007/s00449-026-03358-y}
}
EUVIMED